Cargando…

Paclitaxel and SN‐38 Overcome Cisplatin Resistance of Ovarian Cancer Cell Lines by Down‐regulating the Influx and Efflux System of Cisplatin

Cisplatin (DDP) is one of the key drugs used to treat patients with ovarian cancer, although resistance to DDP can occur. Paclitaxel and SN‐38 (an active metabolite of irinotecan (CPT‐11)) are two drugs that are effective in patients with DDP‐resistant ovarian cancer. To study how these drugs may ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komuro, Yuuki, Udagawa, Yasuhiro, Susumu, Nobuyuki, Aoki, Daisuke, Kubota, Tetsuro, Nozawa, Shiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2001
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926666/ https://www.ncbi.nlm.nih.gov/pubmed/11714450 http://dx.doi.org/10.1111/j.1349-7006.2001.tb02146.x

Ejemplares similares

Regulation of Cisplatin Cytotoxicity by Cu Influx Transporters
por: Abada, Paolo, et al.
Publicado: (2010)

Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa Cells
por: Minagawa, Yukihisa, et al.
Publicado: (1994)

Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells
por: Fujii, Ryu‐ichi, et al.
Publicado: (1994)

Efflux and Influx of Erythrocyte Water
por: Olmstead, Edwin G.
Publicado: (1960)

EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer
por: Wang, Xuemin, et al.
Publicado: (2015)

Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer
por: Wang, Xuemin, et al.
Publicado: (2015)

Relationship of Cation Influxes and Effluxes in Yeast
por: Rothstein, Aser
Publicado: (1974)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux
por: Zhao, Yujie, et al.
Publicado: (2021)

Radiation Recall Dermatitis after Treatment with Paclitaxel and Cisplatin
por: Baek, Seung Woo, et al.
Publicado: (2012)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Culture media, DMSO and efflux affect the antibacterial activity of cisplatin and oxaliplatin
por: Gupta, A., et al.
Publicado: (2022)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
por: Shi, Zhen-duo, et al.
Publicado: (2022)

Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice
por: Tsuji, Takumi, et al.
Publicado: (2022)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells
por: Ho, Winson S., et al.
Publicado: (2016)

Nanosensor Detection of an Immunoregulatory Tryptophan Influx/Kynurenine Efflux Cycle
por: Kaper, Thijs, et al.
Publicado: (2007)

Extracellular and Metabolic Factors Affecting the Efflux and Influx of Erythrocyte Water
por: Olmstead, Edwin G.
Publicado: (1961)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells
por: Schmidtova, Silvia, et al.
Publicado: (2019)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Nanoparticle-Mediated Delivery of Satraplatin to Overcome Cisplatin Drug Resistance
por: Jiang, Xiaohan, et al.
Publicado: (2023)

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
por: Chen, Yi, et al.
Publicado: (2017)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
por: Tu, Lingli, et al.
Publicado: (2013)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix
por: Dana, Rohitashwa, et al.
Publicado: (2016)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Multi-drug-resistance efflux in cisplatin-naive and cisplatin-exposed A2780 ovarian cancer cells responds differently to cell culture dimensionality
por: Koshkin, Vasilij, et al.
Publicado: (2021)

Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers
por: Kim, Kyu Kwang, et al.
Publicado: (2015)

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
por: Risnayanti, Chitra, et al.
Publicado: (2018)

Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1
por: Lin, Xinjian, et al.
Publicado: (2014)

Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model
por: Gomez-Roman, Natividad, et al.
Publicado: (2015)

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens
por: Zheng, Li, et al.
Publicado: (2018)

A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis
por: Fruscio, R, et al.
Publicado: (2008)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
por: Hama, Taketsugu, et al.
Publicado: (2021)

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
por: Rajendran, Ganeshkumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ue2i2lv294jidg8pml60n3une2